Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/26/29	$1.220	+2.52%	15,110
28/26/28	$1.190	+5.31%	21,366
27/26/27	$1.130	-0.88%	8,812
26/26/26	$1.140	+0.88%	25,697
23/26/23	$1.130	+0.89%	29,088

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.190USD

Average target price

26.00USD

Spread / Average Target

+2,084.87%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzamend Neuro, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alzamend Neuro, Inc.

Company calendar

Delayed Nasdaq 11:36:50 29/10/2026 pm IST			5-day change	1st Jan Change
1.220 ^USD	+2.52%		+8.93%	-32.97%

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Market Cap	57.43L 51.44L 47.45L 42.94L 80.3L 55Cr 81.6L 5.66Cr 2.26Cr 29Cr 2.16Cr 2.11Cr 91Cr	P/E 2027 *	-1.13x	P/E 2028 *	-1.37x
Enterprise Value	57.43L 51.44L 47.45L 42.94L 80.3L 55Cr 81.6L 5.66Cr 2.26Cr 29Cr 2.16Cr 2.11Cr 91Cr	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.34%	Yield 2027 *	-	Yield 2028 *	-

11/09	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
20/08	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
18/08	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
04/08	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
23/07	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
22/07	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/07	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
07/04	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
26/03	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
16/03	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
16/03	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
12/03	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
07/03	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

12/23/12	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
27/21/27	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
01/21/01	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Share Price

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news: Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
23/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	+6.86%
1 week	+13.54%
Current month	-26.50%
1 month	-30.13%
3 months	-5.10%
6 months	+19.96%
Current year	-30.13%

1 week	1.1	1.36
1 month	1.1	1.84
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	184.95
5 years	0.84	4,562.86
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	20/11/2018
David Katzoff DFI	Director of Finance/CFO	64	05/08/2022
Henry Nisser LAW	General Counsel	57	01/05/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	26/02/2016
William Horne CHM	Chairman	57	01/06/2021
Stephan Jackman BRD	Director/Board Member	50	01/09/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
26/08/26	Todd Ault	Sell	Founder	-2,000	0.0417%
26/08/26	HYPERSCALE DATA, INC.	Other	Company	0	0%	-
31/07/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+6.86%	+13.54%	-48.20%	-99.27%	57.43L
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	6.41TCr
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	5.55TCr
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	5.3TCr
IQVIA HOLDINGS INC.	-1.58%	-1.38%	+26.01%	+54.93%	4.6TCr
BEONE MEDICINES AG	-0.89%	-3.06%	+17.70%	+98.58%	4.25TCr
REVOLUTION MEDICINES, INC.	+0.22%	+0.87%	+226.32%	+931.77%	4.04TCr
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	3.23TCr
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	3.45TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	2.42TCr
Average	+0.24%	+2.96%	+42.20%	+136.65%	3.93TCr
Weighted average by Cap.	-0.24%	+3.13%	+49.33%	+160.53%

	2027 *	2028 *
Net sales	-	-
Net income	-1.08Cr -96.74L -89.24L -80.76L -1.51Cr -102.85Cr -1.53Cr -11Cr -4.25Cr -54Cr -4.05Cr -3.97Cr -170.48Cr	-1.08Cr -96.74L -89.24L -80.76L -1.51Cr -102.85Cr -1.53Cr -11Cr -4.25Cr -54Cr -4.05Cr -3.97Cr -170.48Cr
Net Debt	-	-

Markets		Quality
Nasdaq	ALZN	Delayed
CBOE	ALZN	Real-time